Patterns of Hepatitis G Viraemia and Liver Disease in Haemophiliacs Previously Exposed to Non-virus Inactivated Coagulation Factor Concentrates

Summary

Hepatitis G virus (HGV), a novel flavivirus, has been implicated as a cause of posttransfusion hepatitis. We have performed a longitudinal study in a cohort of haemophiliacs (n = 68) who previously received non-virus inactivated coagulation factor concentrates to assess both patterns of HGV viraemia and any associated liver disease. Hepatitis C virus (HCV) RNA was present in 58/68 and co-infection with human immunodeficiency virus (HIV) was present in 15/68.

HGV RNA was detected in 17/68 (25%) samples from the mid-1980s. There was no association between either HIV infection (p = 0.74) or co-infection with a particular HCV genotype (p = 0.62). However, there was a relationship between HGV viraemia and the severity of haemophilia (p = 0.0004) with HGV RNA detected in 5/19, 9/16 and 3/32 patients with mild, moderate and severe haemophilia respectively.

A longitudinal study was performed in 15/17 haemophiliacs with HGV viraemia using stored serum samples from the 1980s and 1990s. HGV viraemia persisted in 8/15 and cleared in 7/15 over a variable period of time. A Weibull model was constructed to estimate the duration of HGV viraemia in the study group. The 75th and 90th percentiles for the duration of HGV were estimated to be 8.7 years (95%, confidence interval 4.8-15.7) and 23.6 years (95% confidence interval 11.8-47.1) respectively. Laparoscopic liver inspection/biopsy was performed in 25/68. There was no association between severity of liver disease and HGV viraemia (p = 0.43). This study demonstrates considerable variation in patterns of HGV viraemia in haemophiliacs. We found little evidence to implicate HGV as a major cause of chronic liver disease in haemophiliacs.

• References

• 1 Tedder RS, Briggs M, Ring C, Tuke PW, Jones P, Savidge GF, Rodgers B, Garson JA. Hepatitis C antibody profile and viraemia prevalence in adults with severe haemophilia. Br J Haematol 1991; 79: 512-5.
• 2 Watson HG, Ludlam CA, Rebus S, Zhang LQ, Peutherer JF, Simmonds P. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non virus inactivated factor VIII and IX concentrations. Br J Haematol 1992; 80: 514-8.
• 3 Ahmed MM, Mutimer DJ, Elias E, Linin L, Garrido M, Hubscher S, Jarvis L, Simmonds P, Wilde JT. A combined management protocol for patients with coagulation disorders infected with hepatitis C virus. Br J Haematol 1996; 95: 383-8.
• 4 Hanley JP, Jarvis LM, Andrews J, Dennis R, Hayes P, Lee R, Simmonds P, Piris J, Ludlam CA. Investigation of chronic hepatitis C infection in individuals with haemophilia assessment of invasive and non-invasive methods. Br J Haematol 1996; 94: 159-65.
• 5 Makris M, Preston FE, Rosendaal FR, Underwood JCE, Rice KM, Triger DR. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94: 746-52.
• 6 Simons JN, Leary TP, Dawson GJ, Pilot-Matias TJ, Muerhoff AS, Schlauder GG, Desi SM, Mushahwar IK. Isolation of novel virus-like sequences associated with human hepatitis. Nature Med 1995; 1: 564-9.
• 7 Leary TP, Muerhoff AS, Simons JN, Pilot-Matias TJ, Erker JC, Chalmers ML, Schlauder GG, Dawson GJ, Desai SM, Mushahwar IK. Sequence and genomic organization of GBV-C. A novel member of the flaviviridae associated with human non-A-E hepatitis. J Med Virol 1996; 48: 60-7.
• 8 Linnen J, Wages J, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis P, Karayiannis P, Fung K, Nakatsuji Y, Shih JW, Young L, Piatak Jr M, Hoover C, Fernandez J, Chen S, Zou JC, Morris T, Hyams KC, Ismay S, Lifson DJ, Hess G, Foung SKH, Thomas H, Bradley D, Margolis H, Kim JP. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996; 271: 505-8.
• 9 Jarvis LM, Davidson F, Hanley JP, Healey CJ, Yap PL, Ludlam CA, Simmonds P. Frequency of infection with hepatitis G virus among recipients of plasma products. Lancet 1996; 348: 1352-5.
• 10 Hanley JP, Jarvis LM, Andrews J, Dennis R, Hayes PC, Piris J, Lee R, Simmonds P, Ludlam CA. Interferon for chronic hepatitis C infection in hemophiliacs – Influence of virus load, genotype and liver pathology on response. Blood 1996; 87: 1704-9.
• 11 Jalan R, Harrison DJ, Dillon JF, Elton RA, Finlayson NDC, Hayes PC. Laparoscopy and histology in the diagnosis of chronic liver disease. Q J Med 1995; 88: 559-64.
• 12 Tagariello G, Infantolino D, Biasin MR, Davioli PG, Traldi A. Hepatitis G viral RNA in Italian haemophiliacs with and without hepatitis C infection (letter). Lancet 1996; 348: 760-1.
• 13 Tacke M, Kiyosawa K, Stark K, Schlueter V, Ofenloch-Haehnle B, Hess G, Engel AM. Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet 1997; 349: 318-20.
• 14 Karayiannis P, Pickering J, Chiaramonte M, Thomas HC. Hepatitis G virus infection (letter). Lancet 1997; 349: 954.
• 15 Wang JT, Tsai FC, Lee CZ, Chen PJ, Sheu JC, Wang TH, Chen DS. A prospective study of transfusion-transmitted GB virus C infection: similar frequency but different clinical presentation compared with hepatitis C virus. Blood 1996; 88: 1881-6.